

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. P31824C1D2	PRED. SERIAL NO. <del>10/068,514</del> 10/716,923
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use several sheets if necessary)</i>		APPLICANT Granett, et al.	
		PRED. FILING DATE February 5, 2002	PRED. GROUP ART UNIT 1614

## U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
AS	5,972,944	10/1999	Antonucci, et al.	514	252	
	5,002,953	3/26/91	Hindley			
	5,194,443	3/16/93	Hindley			
	5,232,925	8/3/93	Hindley			
	5,260,445	11/9/93	Hindley			
	5,521,201	5/28/96	Hindley, et al.			
	5,646,169	7/8/97	Hindley, et al.			
	5,741,803	4/21/98	Pool, et al.			
	5,756,525	5/26/98	Hindley, et al.			
	5,910,592	6/8/99	Pool, et al.			
	6,288,095	9/11/01	Hindley, et al.			
	6,166,049	12/26/00	S.A. Smith			
AS	US20020049240	4/25/02	Hindley, et al.			

## FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
AS	WO 98/02159	1/22/98	PCT				
	WO 95/21608	8/17/95	PCT				
	WO 97/05875	2/20/97	PCT				
	WO 97/18811	5/29/97	PCT				
	WO 94/05659	3/17/94	PCT				
	0 796 618 A	9/24/97	EP				
	0 306 228 A	3/8/89	EP				
	0 419 035 A1	3/27/91	EP				
	0 419 035 B1	2/15/95	EP				
	WO 94/25026	11/10/94	PCT				
	WO 95/07694	3/23/95	PCT				
	WO 97/25042	7/17/97	PCT				



## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AS	"R&D Focus Drug News", Dialog File Supplier: File 445 R&D Focus, Accession Nos. 16402 and 14818, 05 May 1997 – 10 March 1997, XP002082979.
	"Rosiglitazone SmithKline Beecham Clinical Data", STN File Supplier: Drugnl: Accession Number 1391 & R&D Focus Drug News, 17 April 1998, XP002082989.
	"The Pink Sheet", Dialog File Supplier: File 187: F-D-C Reports; Accession Number 600160005, 60(16): 20 April 1998, XP002082978.
AS	Berger, et al., "Thiazolidinediones Produce a Conformational Change in Peroxisomal Proliferator-Activated Receptor- $\gamma$ : Binding and Activation Correlate with Antidiabetic Actions in db/db Mice". <i>Endocrinology</i> , 137(10): 4189-4195 (1996). XP000613643.

EXAMINER	DATE CONSIDERED 3/20/04
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. P31824C1D2	PRED. SERIAL NO. <del>10/068,514</del> 10/716923
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use several sheets if necessary)</i>		APPLICANT Granett, et al.	
		PRED. FILING DATE February 5, 2002	PRED. GROUP ART UNIT 1614




## U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	US20030149054	8/7/03	Hindley et al. - Corresponds to previously cited U.S. Patent Appln. No. 10/071,824 (Docket No.: B2368).			
	US20030109552	6/12/03	Buckingham - Corresponds to previously cited U.S. Patent Appln. No. 09/989,798 (Docket No.: P30879).			

## FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Remington's Pharmaceutical Sciences, 15th Edition, 1975, Mack Publishing Company, Chapter 89, pp. 1583-1586.
	Physician's Desk Reference, 54th Edition, 2000, Medical Economics Company, pp. 2980-2984, Citation based on product labeling dated June 15, 1999.
EXAMINER 	
DATE CONSIDERED 3/20/04	
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	